RESEARCH MONOGRAPH · KDC-MN-241

Ulotaront

May 9, 2026 Kodiac biolabs Research Revised May 22, 2026 3 min read

Our opinion on this compound

57/100

TAAR1 agonist that everybody wanted to work and then phase 3 didnt, but the mechanism question is still alive

Ulotaront (SEP-363856) was the compound the field had been waiting for. A TAAR1 agonist with 5-HT1A activity, essentially no D2 affinity, no 5-HT2A affinity, no muscarinic, no histamine. Trace amine-associated receptor 1 had been a hypothetical target for psychosis treatment for years, with preclinical evidence suggesting TAAR1 activation could indirectly modulate dopaminergic firing in a way that produced antipsychotic-like effects without D2 antagonism. Ulotaront was the first compound to actually carry that hypothesis into phase 3.

And then in 2023 the DIAMOND trials reported. The compound essentially didn't separate from placebo on the primary schizophrenia endpoint. Sumitomo and Otsuka discontinued development for schizophrenia, and the field collectively had to grapple with what that failure meant for the TAAR1 hypothesis.

Honestly we don't think it means TAAR1 is dead as a target. The phase 2 signal had been promising enough that the failure in phase 3 might reflect study-design issues, compound-specific dosing issues, or the difficulty of replicating effect sizes from positive smaller trials in larger registration-grade studies. Thats happened to plenty of mechanisms in psychiatry. But it does mean the TAAR1 antipsychotic story is now in a much more guarded place than it was three years ago.

For research, ulotaront remains a useful TAAR1 agonist tool compound with 5-HT1A activity, even though its clinical development has been discontinued. The pharmacology is well characterized in the public literature from the development program, and the selectivity profile is genuinely clean by tool-compound standards.

What we dont know is whether the next-generation TAAR1 compounds will fare differently. Several are in development. The mechanism question hasn't been definitively resolved by ulotaront's phase 3 failure, but the bar for the next compound just got higher.

Sourcing is the practical issue. As a discontinued investigational compound, reference material availability is uncertain and vendor selection is thin. Per-gram costs can be steep. HPLC validation is doable on clean material.

Genuinely interesting compound, genuinely interesting mechanism question, frustrating clinical outcome. Worth keeping on the watchlist as the next TAAR1 agents read out.

Evidence: 55
Mechanism: 78
Reliability: 55
Safety: 72
Sourcing: 45
Value: 40
Signal: 55
Staying power: 55

Plain-language summary Intrigue 76 / 100

Ulotaront (SEP-363856) was an exciting investigational antipsychotic from Sumitomo (Sunovion) that worked through a completely different mechanism than every other drug in its class: activation of the trace amine-associated receptor 1 (TAAR1) plus serotonin 5-HT1A activation, with no measurable activity at dopamine D2 or serotonin 5-HT2A receptors at all. The Phase 2 data published in the New England Journal of Medicine in 2020 generated significant enthusiasm, suggesting it might be the first non-D2 antipsychotic ever to reach approval. The Phase 3 DIAMOND trials read out in 2023 and failed to demonstrate efficacy versus placebo, which was a substantial disappointment for the field. The TAAR1 mechanism remains under active investigation by other companies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

TAAR1 agonist with 5-HT1A agonism

A novel TAAR1 and 5-HT1A agonist; the first non-D2 antipsychotic candidate to reach phase 3 trials.

Abstract

Ulotaront (SEP-363856; (4S)-4-[(R)-(1H-imidazo[2,1-b][1,3]thiazol-6-yl)oxymethyl]-1,2,3,4-tetrahydroquinoline; molecular formula C16H17N3OS; molecular weight 299.39) is a TAAR1 agonist with 5-HT1A agonism developed at Sumitomo (Sunovion) as a non-D2 antipsychotic candidate. The compound has no measurable affinity for D2 or 5-HT2A receptors at therapeutic concentrations, breaking from the dominant pharmacological framework for antipsychotic action. Mechanism: TAAR1 agonism modulates dopaminergic and glutamatergic signaling in the mesolimbic system through indirect mechanisms; 5-HT1A agonism contributes to anxiolytic and possibly procognitive effects. Phase 2 trials in acute schizophrenia (2020) showed efficacy comparable to existing antipsychotics with favorable side effect profile (no weight gain, no EPS, no prolactin elevation); phase 3 DIAMOND trials (announced 2023) failed to meet primary endpoints, leading Sumitomo to halt development. The compound retains research utility as the prototype TAAR1 agonist for academic schizophrenia research. Used as the reference TAAR1/5-HT1A agonist for non-D2 antipsychotic mechanism studies.

Mechanism of action

TAAR1 agonism plus 5-HT1A agonism, no D2 or 5-HT2A activity. Mechanism for antipsychotic action via indirect dopaminergic modulation through TAAR1.

Reported research dose ranges

Investigational; trial doses 50 to 75 mg per oral administration daily.

References

Dedic N, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther 2019.
Koblan KS, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med 2020.
Heffernan MLR, et al. Ulotaront: trace amine-associated receptor 1 (TAAR1) and 5-HT1A receptor agonist. Pharmacol Rev 2022.

Read the full monograph

The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-241 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Ulotaront

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs